<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03293615</url>
  </required_header>
  <id_info>
    <org_study_id>6431</org_study_id>
    <nct_id>NCT03293615</nct_id>
  </id_info>
  <brief_title>Exercise Capacity of Patients With Dermatomyosis</brief_title>
  <acronym>MIDE</acronym>
  <official_title>Exercise Capacity of Patients With Dermatomyosisthe Role of Muscle Mitochondria and Reactive Oxygen Species</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dermatomyositis (DM) patients experience muscle weakness and low aerobic capacities, which&#xD;
      are associated with poor health status and increased mortality. The origin of this muscle&#xD;
      impairment remains unknown.&#xD;
&#xD;
      The investigators hypothesize that mitochondria functioning is impaired in DM muscle and&#xD;
      links with exercise capacities.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the capacity of muscle fibers to consume oxygen in the muscle of patients i) with DM, ii) with other inflammatory myopathy, iii) without neuromuscular disease.</measure>
    <time_frame>Baseline</time_frame>
    <description>This difference in mitochondrial breathing capacity in the muscle will be achieved by: Muscle biopsy</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>Dermatomyositis (DM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with dermatomyositis according to ENMC criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-dermatomyositis inflammatory myopathies</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with other inflammatory myopathy than dermatomyositis according to ENMC criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No myopathy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients without myopathy on muscle biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>exploration</intervention_name>
    <description>Difference of the following parameters in patients i) with DM, ii) with another inflammatory myopathy iii) without neuromuscular disease.</description>
    <arm_group_label>Dermatomyositis (DM)</arm_group_label>
    <arm_group_label>Non-dermatomyositis inflammatory myopathies</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Woman or man&gt; 18 years,&#xD;
&#xD;
          -  Signature of informed consent,&#xD;
&#xD;
          -  Muscle biopsy for suspicion of recent inflammatory myopathy (&lt;6 months) or for&#xD;
             exclusion of neuromuscular pathology.&#xD;
&#xD;
        Prospectively, following the results of the muscle biopsy, the subjects will divided into&#xD;
        three groups meeting the following criteria:&#xD;
&#xD;
          -  &quot;DM&quot; group: DM according to the ENMC criteria;&#xD;
&#xD;
          -  &quot;other inflammatory myopathy&quot; group: polymyositis, autoimmune necrotizing myopathy,&#xD;
             non-specific myositis or inclusion myositis according to the ENMC criteria;&#xD;
&#xD;
          -  Group &quot;no neuromuscular pathology&quot;: i) myalgia and / or intolerance to exercise and&#xD;
             ii) normal neuromuscular examination, iii) no increase in blood creatine kinase level,&#xD;
             iv) absence of electromyographic abnormality, v) histological Muscle mass.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Taking an immunomodulatory treatment within 6 months before inclusion,&#xD;
&#xD;
          -  Paraneoplastic form of the disease,&#xD;
&#xD;
          -  Presence of associated interstitial pneumonitis,&#xD;
&#xD;
          -  Neuromuscular pathology different from inflammatory myopathy,&#xD;
&#xD;
          -  Unbalanced cardiovascular disease,&#xD;
&#xD;
          -  Impossibility of giving the subject informed information (subject in an emergency&#xD;
             situation, difficulty in understanding the subject, ...),&#xD;
&#xD;
          -  Subject under safeguard of justice,&#xD;
&#xD;
          -  Subject under tutelage or under curators,&#xD;
&#xD;
          -  Pregnancy (positive pregnancy test)&#xD;
&#xD;
          -  Breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Meyer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Les HÃ´pitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain Meyer, MD</last_name>
    <phone>00333 6 76 95 31 67</phone>
    <email>alain.meyer1@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meyer</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2017</study_first_submitted>
  <study_first_submitted_qc>September 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatomyositis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

